Alector Announces Closing Of Series D Financing

SAN FRANCISCO--(BUSINESS WIRE)--Alector LLC, a biotech company pioneering the discovery and development of first-in-class, immuno-modulatory therapies for Alzheimer’s disease and other neurodegenerative disorders, today announced that it has raised $29.5 million in a Series D financing. After having completed a Series C financing of $32 million earlier in the year, this financing brings the total amount of capital raised in 2015 to $62M. The financing was led by the Dementia Discovery Fund, with new investors Amgen Ventures and AbbVie joining the syndicate.

Back to news